Kimberly H Allison

List of Publications by Citations

76 papers	8,220 citations	30 h-index	80 g-index
80 ext. papers	10,475 ext. citations	6 avg, IF	5.53 L-index

#	Paper	IF	Citations
76	Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *Journal of Clinical Oncology*, **2013**, 31, 3997-4013	2.2	2593
75	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. *Cell*, **2015**, 163, 506-19	56.2	1055
74	Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *Archives of Pathology and Laboratory Medicine*, **2014**, 138, 241-56	5	738
73	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. *Journal of Clinical Oncology*, **2018**, 36, 2105-2122	2.2	646
72	Extracellular matrix stiffness and composition jointly regulate the induction of malignant phenotypes in mammary epithelium. *Nature Materials*, **2014**, 13, 970-8	27	515
71	Diagnostic concordance among pathologists interpreting breast biopsy specimens. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1122-32	27.4	343
70	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. *Archives of Pathology and Laboratory Medicine*, **2018**, 142, 1364-1382	5	295
69	Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. *Journal of Clinical Oncology*, **2020**, 38, 1346-1366	2.2	249
68	The 2019 World Health Organization classification of tumours of the breast. *Histopathology*, **2020**, 77, 181-185	7.3	131
67	Angiosarcoma involving the gastrointestinal tract: a series of primary and metastatic cases. *American Journal of Surgical Pathology*, **2004**, 28, 298-307	6.7	94
66	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. *Journal of Pathology*, **2020**, 250, 667-684	9.4	83
65	Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. *Archives of Pathology and Laboratory Medicine*, **2020**, 144, 545-563	5	82
64	Frequency and upgrade rates of atypical ductal hyperplasia diagnosed at stereotactic vacuum-assisted breast biopsy: 9-versus 11-gauge. *American Journal of Roentgenology*, **2009**, 192, 229-34	5.4	79
63	Molecular pathology of breast cancer: what a pathologist needs to know. *American Journal of Clinical Pathology*, **2012**, 138, 770-80	1.9	66
62	Diagnosing endometrial hyperplasia: why is it so difficult to agree?. *American Journal of Surgical Pathology*, **2008**, 32, 691-8	6.7	66
61	The molecular basis of breast cancer pathological phenotypes. *Journal of Pathology*, **2017**, 241, 375-391	9.4	62
60	Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations. *Journal of Clinical Oncology*, **2016**, 34, 2303-11	2.2	61

59	Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity. *American Journal of Clinical Pathology*, **2011**, 136, 864-71	1.9	59
58	HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. *Journal of Oncology Practice*, **2018**, 14, 437-441	3.1	56
57	Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial. *JAMA Oncology*, **2017**, 3, 969-973	13.4	54
56	Understanding diagnostic variability in breast pathology: lessons learned from an expert consensus review panel. *Histopathology*, **2014**, 65, 240-51	7.3	54
55	Eye movements as an index of pathologist visual expertise: a pilot study. *PLoS ONE*, **2014**, 9, e103447	3.7	54
54	'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study. *Modern Pathology*, **2017**, 30, 227-235	9.8	53
53	Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases. *American Journal of Clinical Pathology*, **2010**, 134, 284-92	1.9	51
52	Atypical ductal hyperplasia on vacuum-assisted breast biopsy: suspicion for ductal carcinoma in situ can stratify patients at high risk for upgrade. *Human Pathology*, **2011**, 42, 41-50	3.7	46
51	Epithelioid trophoblastic tumor: review of a rare neoplasm of the chorionic-type intermediate trophoblast. *Archives of Pathology and Laboratory Medicine*, **2006**, 130, 1875-7	5	39
50	Variability in Pathologists' Interpretations of Individual Breast Biopsy Slides: A Population Perspective. *Annals of Internal Medicine*, **2016**, 164, 649-55	8	37
49	Optimized Protocol for Quantitative Multiple Reaction Monitoring-Based Proteomic Analysis of Formalin-Fixed, Paraffin-Embedded Tissues. *Journal of Proteome Research*, **2016**, 15, 2717-28	5.6	35
48	Development of a diagnostic test set to assess agreement in breast pathology: practical application of the Guidelines for Reporting Reliability and Agreement Studies (GRRAS). *BMC Womens Health*, **2013**, 13, 3	2.9	34
47	Trends in breast biopsy pathology diagnoses among women undergoing mammography in the United States: a report from the Breast Cancer Surveillance Consortium. *Cancer*, **2015**, 121, 1369-78	6.4	30
46	Breast cancer stem cells: are we ready to go from bench to bedside?. *Histopathology*, **2016**, 68, 119-37	7.3	27
45	The diagnostic challenge of low-grade ductal carcinoma in situ. *European Journal of Cancer*, **2017**, 80, 39-47	7.5	25
44	DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas. *Npj Breast Cancer*, **2016**, 2, 16007	7.8	25
43	Reply to E.A. Rakha et al. *Journal of Clinical Oncology*, **2015**, 33, 1302-4	2.2	24
42	Second opinion in breast pathology: policy, practice and perception. *Journal of Clinical Pathology*, **2014**, 67, 955-60	3.9	24

41	Quantitative Image Analysis of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry for Breast Cancer: Guideline From the College of American Pathologists. *Archives of Pathology and Laboratory Medicine*, **2019**, 143, 1180-1195	5	22
40	A Randomized Study Comparing Digital Imaging to Traditional Glass Slide Microscopy for Breast Biopsy and Cancer Diagnosis. *Journal of Pathology Informatics*, **2017**, 8, 12	4.4	21
39	Second opinion strategies in breast pathology: a decision analysis addressing over-treatment, under-treatment, and care costs. *Breast Cancer Research and Treatment*, **2018**, 167, 195-203	4.4	18
38	Evaluation of 12 strategies for obtaining second opinions to improve interpretation of breast histopathology: simulation study. *BMJ, The*, **2016**, 353, i3069	5.9	18
37	Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? A review. *Applied Immunohistochemistry and Molecular Morphology*, **2008**, 16, 329-43	1.9	18
36	Characteristics and clinical outcomes of pleomorphic lobular carcinoma in situ of the breast. *Breast Journal*, **2018**, 24, 66-69	1.2	17
35	Pretreatment Tattoo Marking of Suspicious Axillary Lymph Nodes: Reliability and Correlation with Sentinel Lymph Node. *Annals of Surgical Oncology*, **2019**, 26, 2452-2458	3.1	16
34	Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.. *Journal of Clinical Oncology*, **2022**, JCO2200069	2.2	15
33	Defining an appropriate threshold for the diagnosis of serous borderline tumor of the ovary: when is a full staging procedure unnecessary?. *International Journal of Gynecological Pathology*, **2008**, 27, 10-7	3.2	14
32	An unusual case of multiple giant myelolipomas: clinical and pathogenetic implications. *Endocrine Pathology*, **2003**, 14, 93-100	4.2	14
31	Preoperative MRI improves prediction of extensive occult axillary lymph node metastases in breast cancer patients with a positive sentinel lymph node biopsy. *Academic Radiology*, **2014**, 21, 92-8	4.3	13
30	Superficial malignant peripheral nerve sheath tumor: a rare and challenging diagnosis. *American Journal of Clinical Pathology*, **2005**, 124, 685-92	1.9	13
29	Histological features associated with diagnostic agreement in atypical ductal hyperplasia of the breast: illustrative cases from the B-Path study. *Histopathology*, **2016**, 69, 1028-1046	7.3	12
28	Surgical implications and variability in the use of the flat epithelial atypia diagnosis on breast biopsy specimens. *Breast*, **2017**, 34, 34-43	3.6	10
27	Diagnostic Reproducibility: What Happens When the Same Pathologist Interprets the Same Breast Biopsy Specimen at Two Points in Time?. *Annals of Surgical Oncology*, **2017**, 24, 1234-1241	3.1	10
26	Rosai-Dorfman Disease of the Breast With Variable IgG4+ Plasma Cells: A Diagnostic Mimicker of Other Malignant and Reactive Entities. *American Journal of Surgical Pathology*, **2019**, 43, 1653-1660	6.7	10
25	Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions. *Modern Pathology*, **2018**, 31, 562-568	9.8	10
24	Pupil diameter changes reflect difficulty and diagnostic accuracy during medical image interpretation. *BMC Medical Informatics and Decision Making*, **2016**, 16, 77	3.6	8

23	Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks. *American Journal of Clinical Pathology*, **2017**, 148, 199-207	1.9	8
22	Estrogen receptor expression in breast cancer: we cannot ignore the shades of gray. *American Journal of Clinical Pathology*, **2008**, 130, 853-4	1.9	8
21	Identifying and processing the gap between perceived and actual agreement in breast pathology interpretation. *Modern Pathology*, **2016**, 29, 717-26	9.8	7
20	Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis. *Modern Pathology*, **2020**, 33, 1518-1526	9.8	6
19	Updates on breast biomarkers.. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2022**, 480, 163	5.1	6
18	The Influence of Disease Severity of Preceding Clinical Cases on Pathologists' Medical Decision Making. *Medical Decision Making*, **2017**, 37, 91-100	2.5	5
17	Integrated genomic characterization of ERBB2/HER2 alterations in invasive breast carcinoma: a focus on unusual FISH groups. *Modern Pathology*, **2020**, 33, 1546-1556	9.8	5
16	Breast Cancer Prognostic Factors in the Digital Era: Comparison of Nottingham Grade using Whole Slide Images and Glass Slides. *Journal of Pathology Informatics*, **2019**, 10, 11	4.4	5
15	Characteristics associated with requests by pathologists for second opinions on breast biopsies. *Journal of Clinical Pathology*, **2017**, 70, 947-953	3.9	4
14	Ancillary Prognostic and Predictive Testing in Breast Cancer: Focus on Discordant, Unusual, and Borderline Results. *Surgical Pathology Clinics*, **2018**, 11, 147-176	3.9	4
13	Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues. *Clinical Chemistry*, **2021**, 67, 1008-1018	5.5	3
12	Nodular fasciitis of the breast: clinicopathologic and molecular characterization with identification of novel USP6 fusion partners. *Modern Pathology*, **2021**, 34, 1865-1875	9.8	3
11	Prognostic and predictive parameters in breast pathology: a pathologist's primer. *Modern Pathology*, **2021**, 34, 94-106	9.8	3
10	HER2 Dual In Situ Hybridization: Correlations and Cautions. *Archives of Pathology and Laboratory Medicine*, **2020**, 144, 1525-1534	5	2
9	HER2 Testing: Insights From Pathologists' Perspective on Technically Challenging HER2 FISH Cases. *Applied Immunohistochemistry and Molecular Morphology*, **2021**, 29, 635-642	1.9	1
8	The Milky Way Sign: A New Diagnostic Finding of Ductal Carcinoma in situ on Digital Breast Tomosynthesis. *Breast Journal*, **2016**, 22, 349-51	1.2	1
7	In Reply. *Archives of Pathology and Laboratory Medicine*, **2019**, 143, 413-414	5	
6	Interview: Breast cancer: the pathologist point of view. *Breast Cancer Management*, **2013**, 2, 363-366	0.7	

5	Intraductal Proliferations (DCIS, ADH, and UDH) **2016**, 337-375	
4	Tissue sampling frequency and breast pathology diagnoses following mammography: Time trends and age group analysis from the Breast Cancer Surveillance Consortium (BCSC).. *Journal of Clinical Oncology*, **2013**, 31, 559-559	2.2
3	Reply to C. Murray et al and V. Martin et al. *Journal of Clinical Oncology*, **2018**, JCO1801163	2.2
2	Surgical Excision Versus Neoadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma In Situ (NORDIS). *Annals of Surgical Oncology*, **2021**, 1	3.1
1	Abstract OT1-09-01: A randomized study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In Situ (NORDIS). *Cancer Research*, **2022**, 82, OT1-09-01-OT1-09-01	10.1